Clene Inc. Common Stock (CLNN)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses with consistent earnings and a margin of safety. Clene, despite the supplied Consumer Defensive/Packaged Foods label, describes itself as a clinical-stage pharmaceutical company. In fiscal 2023, revenue was $654,000 and net loss was $49.5M; in fiscal 2024, revenue was $342,000 and net loss was $39.4M; in fiscal 2025, revenue was $200,000 and net loss was $26.2M. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $90,000 and net loss was $13.4M. That is not a business with a moat; it is a pipeline burning cash. Trailing free cash flow was -$15.9M, and FairStock's FCF yield was -36.6% against a $43.6M market cap at the 2026-10-13 close of $3.39. The FairStock P/E is -0.96 because there are no positive earnings. The FairStock Piotroski F-Score is 4/9, Altman Z-Score is -19.70, and the overall FairStock Score is 26/100, all signaling weak financial health. The computed Lynch category is none, since the company lost money in each of the last four years. Valuation by earnings is impossible; the market price rests on clinical hope for CNM-Au8. That can be a lottery ticket, not an investment with a margin of safety. Graham wanted to buy dollars for fifty cents; here I cannot identify the dollar. Buffett would ask for a durable competitive advantage, consistent profits, and capable capital allocation. Clene has completed Phase 2 trials, but no approved product, minimal revenue, and relentless losses. I would watch trial outcomes and financing, not the stock chart. Until the science and balance sheet prove themselves, this remains speculation.

In plain English: Clene is a clinical-stage drug company trying to develop nanotech-based treatments, with its lead candidate being studied in ALS and other diseases. The business looks weak today because it earns almost no revenue and loses millions of dollars every year. At $3.39, the price looks speculative rather than cheap based on the tiny sales and continuing losses shown in the figures.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer